Advertisement
Regulatory
Subscribe to Regulatory
View Sample

FREE Email Newsletter

Tysabri (natalizumab): Update of Healthcare Professional Information

April 22, 2011 9:30 am | by U.S. Food & Drug Administration | News | Comments

Label provides new information about the size of the risk of PML, rates of PML according to number of infusions, and the association of risk with other drugs that suppress immune system.

Consumer Information on: Valiant & #xae; Thoracic Stent Graft with the Captiva Delivery System - P100040

April 20, 2011 11:30 am | by U.S. Food & Drug Administration | News | Comments

The Valiant® Thoracic Stent Graft with the Captivia Delivery System is an endovascular stent graft2 and is used to repair fusiform aneurysms or saccular aneurysms/penetrating ulcers of the aorta3 in the chest. The Valiant® Thoracic Stent Graft is made...

Summary Information for: Valiant & #xae; Thoracic Stent Graft with the Captiva Delivery System

April 20, 2011 10:30 am | by U.S. Food & Drug Administration | News | Comments

Labeling, Approval Order, and Summary of Safety and Effectiveness for Valiant® Thoracic Stent Graft with the Captiva Delivery System (P100040).

Advertisement

Summary Information for: Pipeline? Embolization Device

April 20, 2011 10:30 am | by U.S. Food & Drug Administration | News | Comments

Labeling, Approval Order, and Summary of Safety and Effectiveness for Pipeline? Embolization Device (P100018).

Medical Device Data Systems(2)

April 19, 2011 3:31 pm | by U.S. Food & Drug Administration | News | Comments

Medical Device Data Systems (MDDS) are hardware or software products that transfer, store, convert formats, and display medical device data. An MDDS does not modify the data or modify the display of the data, and it does not by itself control the...

Steris System 1 Processor: 6 Month Extension for Healthcare Facilities To Transition to Legally-Marketed Alternatives

April 19, 2011 8:30 am | by U.S. Food & Drug Administration | News | Comments

FDA has extended the transition period to February 2, 2012. All healthcare facilities must be transitioned from Steris Corporation?s modified System 1 processor (SS1) to legally-marketed alternative devices by that time.

MedPAC Vote Could Mean Less Innovation for Imaging Devices

April 15, 2011 2:30 pm | by U.S. Food & Drug Administration | News | Comments

Recommendations from the Medicare Payment Advisory Commission (MedPAC) could curtail use of medical imaging devices.

eSource Guidance Doesn & #8217;t Reflect Current Practice, Industry Says

April 15, 2011 2:30 pm | by U.S. Food & Drug Administration | News | Comments

Manufacturers commenting on an FDA draft guidance addressing electronic data from clinical trials say the guidance is out of sync with current capabilities and practices for data capture and lacks information about the sponsor’s role in reviewing data.

Advertisement

Lansoprazole Delayed-Release Orally Disintegrating Tablets by Teva Pharmaceuticals: Letter to Healthcare Professionals - Clogged, Blocked Oral Syringes and Feeding Tubes

April 15, 2011 6:30 am | by U.S. Food & Drug Administration | News | Comments

Tablets may not fully disintegrate when water is added, and/or they may disintegrate but later form clumps which can adhere to the inside walls of oral syringes and feeding tubes.

Topamax (topiramate): Recall - Musty Odor

April 15, 2011 4:30 am | by U.S. Food & Drug Administration | News | Comments

Two lots of topiramate 100mg tablets recalled, reports of temporary gastrointestinal symptoms.

Tumor Necrosis Factor (TNF) blockers, Azathioprine and/or Mercaptopurine: Update on Reports of Hepatosplenic T-Cell Lymphoma in Adolescents and Young Adults

April 14, 2011 7:30 am | by U.S. Food & Drug Administration | News | Comments

FDA continues to receive reports of a rare cancer of white blood cells.

Penumbra Coil 400 by Penumbra Inc.: Class 1 Recall - Premature Detachment of the Coil(2)

April 13, 2011 3:31 pm | by U.S. Food & Drug Administration | News | Comments

Premature detachment of the coil may cause the coil to unintentionally migrate. This can lead to serious injury including blood clots and stroke.

Axxent FlexiShield Mini by iCAD (formerly Xoft Inc.): Recall- Product May Shed Particles of Tungsten

April 13, 2011 2:30 pm | by U.S. Food & Drug Administration | News | Comments

After use for IORT in breast tissue, these particles can be mistaken for suspicious calcifications during follow up X-rays or scans.

Advertisement

Benzocaine Topical Products: Sprays, Gels and Liquids: Risk of Methemoglobinemia

April 7, 2011 6:30 am | by U.S. Food & Drug Administration | News | Comments

FDA continues to receive reports of methemoglobinemia, a serious and potentially fatal adverse effect, associated with benzocaine products.

Yervoy (ipilimumab): Risk Evaluation and Mitigation Strategy (REMS) - Severe Immune-Mediated Adverse Reactions

April 6, 2011 7:30 am | by U.S. Food & Drug Administration | News | Comments

The most common severe reactions include enterocolitis, hepatitis, dermatitis (including toxic epidermal necrolysis), neuropathy, and endocrinopathy.

Best Enhancer: Recall – Undeclared Drug Ingredient

April 5, 2011 4:31 am | by U.S. Food & Drug Administration | News | Comments

Products marketed as dietary supplements contain undeclared analogue of sildenafil, a drug which may interact with nitrates found in some prescription drugs and lower blood pressure to dangerous levels.

Mikro-Tip Angiographic Catheter, Model SPC-454D and SPC-454F by Millar Instruments Inc.: Class 1 Recall

April 1, 2011 4:31 am | by U.S. Food & Drug Administration | News | Comments

Small particles (debris) may be found inside the catheter and potentially travel (embolize) from the catheter to tissues, blood vessels, limbs and organs which can result in serious injury and /or death.

Heartstring II Proximal Seal System (HS-1045) by Maquet Cardiovascular, LLC: Recall - Insufficient Adhesive

April 1, 2011 4:30 am | by U.S. Food & Drug Administration | News | Comments

The deployment tube may detach during use and may result in the failure of the product to operate, This may cause serious injury and/or death.

Consumer Information on: Medtronic & #xae; InterStim & #xae; Therapy System - P080025

March 31, 2011 6:30 am | by U.S. Food & Drug Administration | News | Comments

The InterStim® Therapy System is a surgically implanted device used to help a patient reduce the number of bowel accidents (fecal incontinence)2. The InterStim® Therapy System has several components: a neurostimulator which delivers an electrical pulse...

Meds IV Pharmacy, IV Compounded Products Recall: Outbreak of Serratia Marcescens Bacteremia in Alabama Hospitals

March 30, 2011 11:30 am | by U.S. Food & Drug Administration | News | Comments

Use of contaminated products may lead to bacterial infection of the blood.

X-Hero and Male Enhancer: Recall - Undeclared Drug Ingredient

March 29, 2011 7:30 am | by U.S. Food & Drug Administration | News | Comments

Products marketed as dietary supplement contain drug ingredients sulfosildenafil or tadalafil, which may interact with nitrates found in some prescription drugs and lower blood pressure to dangerous levels.

Soladek Vitamin Solution: Unapproved Product May Contain Dangerously High Levels of Vitamins A and D

March 29, 2011 4:31 am | by U.S. Food & Drug Administration | News | Comments

Reports of consumers experiencing decreased renal function, elevated levels of calcium in the blood, fatigue, heart arrhythmia, vomiting, and diarrhea.

Guidance for Industry and FDA Staff - Class II Special Controls Guidance Document: Ovarian Adnexal Mass Assessment Score Test System

March 23, 2011 8:30 am | by U.S. Food & Drug Administration | News | Comments

This document was developed as a special controls guidance to support the classification of ovarian adnexal mass assessment score test system into class II (special controls). An ovarian adnexal mass assessment score test system measures one or more...

Town Hall Discussion With the Director of CDRH and Other Senior Center Management, May 5, 2011

March 14, 2011 11:31 am | by U.S. Food & Drug Administration | News | Comments

The objective of this public meeting is to present the CDRH FY 2010 Priorities. In addition, FDA is interested in engaging in discussions about issues that are of importance to the medical device community. CDRH wishes to obtain feedback/ideas for...

Class I, II Devicemakers Must Continue Malfunction Reports

March 11, 2011 1:31 pm | by U.S. Food & Drug Administration | News | Comments

Manufacturers and importers of all devices must continue to submit malfunction reports as they await a promised easing of requirements for Class I devices and Class II devices that are not permanently implantable, life supporting or life sustaining.

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading